Zhejiang Dayang Biotech Group Co (003017) — Cash Flow-to-Debt Ratio
Zhejiang Dayang Biotech Group Co (003017) has a Cash Flow-to-Debt Ratio of 0.00x as of September 2025, meaning its operating cash flow of CN¥638.25K could theoretically repay 0% of its total liabilities (CN¥650.82 Million) in one year. See 003017 FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Zhejiang Dayang Biotech Group Co Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Zhejiang Dayang Biotech Group Co across 13 annual periods. Also explore Zhejiang Dayang Biotech Group Co equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Zhejiang Dayang Biotech Group Co (2013–2025)
Year-by-year debt coverage analysis for Zhejiang Dayang Biotech Group Co. For market capitalisation and broader financial context, see market value of Zhejiang Dayang Biotech Group Co.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | CN¥160.11 Million | CN¥681.72 Million | ▲ +113.0% |
| 2024 | 0.11x | CN¥66.19 Million | CN¥600.40 Million | ▼ -67.5% |
| 2023 | 0.34x | CN¥182.42 Million | CN¥538.47 Million | ▲ +92.8% |
| 2022 | 0.18x | CN¥91.89 Million | CN¥522.92 Million | ▲ +291.7% |
| 2021 | -0.09x | CN¥-35.16 Million | CN¥383.64 Million | ▼ -122.1% |
| 2020 | 0.42x | CN¥112.49 Million | CN¥270.67 Million | ▼ -45.8% |
| 2019 | 0.77x | CN¥113.09 Million | CN¥147.51 Million | ▲ +218.3% |
| 2018 | 0.24x | CN¥38.77 Million | CN¥160.99 Million | ▼ -13.2% |
| 2017 | 0.28x | CN¥48.64 Million | CN¥175.37 Million | ▼ -22.2% |
| 2016 | 0.36x | CN¥84.63 Million | CN¥237.37 Million | ▲ +81.4% |
| 2015 | 0.20x | CN¥48.95 Million | CN¥249.12 Million | ▼ -9.3% |
| 2014 | 0.22x | CN¥57.73 Million | CN¥266.43 Million | ▼ -40.0% |
| 2013 | 0.36x | CN¥91.64 Million | CN¥253.93 Million | — |